# Bevacizumab and Gemcitabine Combined With Either Cetuximab or Erlotinib in Treating Patients With Advanced Pancreatic Cancer

> **NCT00091026** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 143 (actual)

## Conditions studied

- Adenocarcinoma of the Pancreas
- Recurrent Pancreatic Cancer
- Stage II Pancreatic Cancer
- Stage III Pancreatic Cancer
- Stage IV Pancreatic Cancer

## Interventions

- **BIOLOGICAL:** cetuximab
- **DRUG:** gemcitabine hydrochloride
- **BIOLOGICAL:** bevacizumab
- **DRUG:** erlotinib hydrochloride

## Key facts

- **NCT ID:** NCT00091026
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-07
- **Primary completion:** 2011-01
- **Final completion:** 2011-01
- **Target enrollment:** 143 (ACTUAL)
- **Last updated:** 2014-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00091026

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00091026, "Bevacizumab and Gemcitabine Combined With Either Cetuximab or Erlotinib in Treating Patients With Advanced Pancreatic Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00091026. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*